Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy (Q34866510)

5 August 2017

title

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy (English)

1 reference

5 August 2017

Jeffrey S Ross

1

1 reference

5 August 2017

Kai Wang

2

1 reference

5 August 2017

Rami N Al-Rohil

3

1 reference

5 August 2017

Tipu Nazeer

4

1 reference

5 August 2017

Christine E Sheehan

5

1 reference

5 August 2017

Geoff A Otto

6

1 reference

5 August 2017

Jie He

7

1 reference

5 August 2017

Gary Palmer

8

1 reference

5 August 2017

Roman Yelensky

9

1 reference

5 August 2017

Doron Lipson

10

1 reference

5 August 2017

Siraj Ali

11

1 reference

5 August 2017

Sohail Balasubramanian

12

1 reference

5 August 2017

John A Curran

13

1 reference

5 August 2017

Lazlo Garcia

14

1 reference

5 August 2017

Kristen Mahoney

15

1 reference

5 August 2017

Sean R Downing

16

1 reference

5 August 2017

Matthew Hawryluk

17

1 reference

5 August 2017

Vincent A Miller

18

1 reference

5 August 2017

Philip J Stephens

19

1 reference

5 August 2017

publication date

26 July 2013

1 reference

5 August 2017

1 reference

5 August 2017

volume

27

1 reference

5 August 2017

issue

2

1 reference

5 August 2017

page(s)

271-280

1 reference

5 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Environmental factors promoting bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Environmental factors and genetic susceptibility promote urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

The 2004 WHO classification of bladder tumors: a summary and commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Diagnosis and treatment of bladder cancer: how can we improve?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Intravesical therapies for bladder cancer - indications and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Current status of molecular markers for prognostication and outcome in invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Bladder cancer detection using FISH (UroVysion assay).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Deep clonal profiling of formalin fixed paraffin embedded clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Whole cancer genome sequencing by next-generation methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

The Sequence Alignment/Map format and SAMtools

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Transforming fusions of FGFR and TACC genes in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

FOXO1–FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Altered Splicing of FGFR1 Is Associated with High Tumor Grade and Stage and Leads to Increased Sensitivity to FGF1 in Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Urothelial tumorigenesis: a tale of divergent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Altered Expression of Retinoblastoma Protein and Known Prognostic Variables in Locally Advanced Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Role of anti-Her-2 therapy in bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Raf kinases in cancer-roles and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

Delays in diagnosis and bladder cancer mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

7 January 2021

Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

7 January 2021

The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

7 January 2021

The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

7 January 2021

Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer.

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

7 January 2021

p53 expression in patients with advanced urothelial cancer of the urinary bladder

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

7 January 2021

Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

7 January 2021

Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer

1 reference

https://api.crossref.org/works/10.1038/MODPATHOL.2013.135

7 January 2021

10.1038/MODPATHOL.2013.135

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1025381432

0 references

1 reference